• Elizabet Méndez-Eirín, Eduardo Barge-Caballero, María Jesús Paniagua-Martín, Gonzalo Barge-Caballero, David Couto-Mallón, Zulaika Grille-Cancela, Paula Blanco-Canosa, Angelina Cañizares-Castellanos, Miguel González Barbeito, Ana Vanesa Aller Fernández, José Manuel Vázquez-Rodríguez, and María Generosa Crespo-Leiro.
• Servicio de Cardiología, Complejo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España. Electronic address: Elizabet.Mendez.Eirin@sergas.es.
• Med Clin (Barc). 2020 May 22; 154 (10): 381-387.

Introduction And ObjectivesTo assess the risk factors of cytomegalovirus (CMV) infection after heart transplant (HT) and its influence on long-term prognosis.MethodsWe conducted a retrospective single-centre study of 222 HT recipients. Risk factors for CMV infection were identified by means of multivariable Cox́s regression. Kaplan-Meier analysis and Cox́s regression were used to assess the long-term prognostic impact of CMV infection during the first post-transplant year.ResultsDonor-recipient CMV serologic matching (hazard ratio [HR] 1.92, 95% confidence interval [95% CI] 1.2-3.09, p=.007), recipient age (HR 1.02, 95% CI: 1.00-1.1, p=.02), diabetes mellitus (HR 1.86, 95% CI: 1.4-3.05, p=.01), pre-transplant circulatory support (HR 1.59, 95% CI: 1.06-2.38, p=.03) and the use of tacrolimus (HR 1.64, 95% CI: 1.13-2.36, p=.009) were independently associated with increased risk of CMV infection. CMV infection during the first year post-HT was not associated with worse transplant outcomes in terms of mortality, incidence of heart failure, cardiac allograft vasculopathy or acute rejection.ConclusionsCMV infection was not associated with impaired long-term prognosis after HT.Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

23 keywords...

hide…